AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23538154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TR and TF)
Number of subjects: 40
Study 21565557 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcarrier-bound human retinal pigment epithelial (RPE) cells transplantation
Number of subjects: 71
Study 21565557 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 71
Study 18795378 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day Vitamin D3
Number of subjects: 45
Study 18795378 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day Vitamin D3
Number of subjects: 45
Study 18795378 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU/day Vitamin D3
Number of subjects: 45
Study 17088399 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter serum gentamicin concentration
Number of subjects: 45
Study 17088399 — intervention group
Group type: COMPARATOR
Intervention: Peripheral serum gentamicin concentration
Number of subjects: 45
Study 17088399 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter sample result
Number of subjects: 45
Study 15122592 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of IGF-I (highest quartile)
Number of subjects: 69
Study 15122592 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of IGFBP-3
Number of subjects: 69
Study 15122592 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for IGFBP-3 or IGF-I
Number of subjects: 69
Study 11157836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (800 microg)
Number of subjects: 80
Study 11157836 — intervention group
Group type: COMPARATOR
Intervention: Surgical curettage (control)
Number of subjects: 80
Study 9212354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 33
Study 9212354 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 33
Study 8361248 — intervention group
Group type: EXPERIMENTAL
Intervention: VA‐ADHC
Number of subjects: 0
Study 8361248 — intervention group
Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 0
Study 3017039 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1 before surgery, 2 micrograms kg‐1 after cardiopulmonary by‐pass and 1 microgram kg‐1 when the skin was sutured.
Number of subjects: 40
Study 3017039 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 3017039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 40
Study 31892526 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of total plasma apoC3
Number of subjects: 995
Study 31892526 — intervention group
Group type: EXPERIMENTAL
Intervention: Total apoA1 levels
Number of subjects: 995
Study 31892526 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of apoA1 in HDL and its apolipoprotein‐defined subspecies
Number of subjects: 995
Study 31068221 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 6000
Study 31068221 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 6000
Study 29025835 — intervention group
Group type: EXPERIMENTAL
Intervention: CML-enhanced maternal milk formulation
Number of subjects: 1500
Study 29025835 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard maternal milk formulation
Number of subjects: 1500
Study 29025835 — intervention group
Group type: COMPARATOR
Intervention: No maternal milk intervention with standard pregnancy advice
Number of subjects: 1500
Study 26421525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser treatment
Number of subjects: 60
Study 26421525 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 23160656 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 °C (mild-cold)
Number of subjects: 16
Study 23160656 — intervention group
Group type: COMPARATOR
Intervention: 21 °C (control)
Number of subjects: 16
Study 21481024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization
Number of subjects: 60
Study 21481024 — intervention group
Group type: COMPARATOR
Intervention: Milk-free diet (Control)
Number of subjects: 60
Study 19784514 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation (NE)
Number of subjects: 40
Study 19784514 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US)
Number of subjects: 40
Study 17000686 — intervention group
Group type: EXPERIMENTAL
Intervention: Abagovomab 2.0 mg
Number of subjects: 42
Study 17000686 — intervention group
Group type: EXPERIMENTAL
Intervention: Abagovomab 0.2 mg
Number of subjects: 42
Study 17000686 — intervention group
Group type: EXPERIMENTAL
Intervention: Abagovomab (route i.m. or s.c.)
Number of subjects: 42
Study 17000686 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 42
Study 15366639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 3454
Study 15366639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3454
Study 12566890 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost additive therapy
Number of subjects: 35
Study 9701293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dihydroergotamine (DHE)
Number of subjects: 171
Study 9701293 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg meperidine (MEP)
Number of subjects: 171
Study 7981460 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg daily
Number of subjects: 292
Study 7981460 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg daily
Number of subjects: 292
Study 7981460 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg daily
Number of subjects: 292
Study 7981460 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene (pooled 40 + 100 mg)
Number of subjects: 292
Study 7981460 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg
Number of subjects: 292
Study 7981460 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg
Number of subjects: 292
Study 7981460 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene (all dosages)
Number of subjects: 292
Study 2657320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile Insulin (PI) - 75% of 32 mU/kg/h delivered as 40-second pulses every 13 minutes
Number of subjects: 6
Study 2657320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) - 32 mU/kg/h continuous infusion
Number of subjects: 6
Study 2657320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) - second 12 CI infusions
Number of subjects: 6
Study 2657320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile Insulin (PI) followed by Continuous Insulin (CI)
Number of subjects: 6
Study 2657320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) followed by Continuous Insulin (CI)
Number of subjects: 6
Study 2657320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile Insulin (PI) - first infusion
Number of subjects: 6
Study 2657320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) - first infusion
Number of subjects: 6
Study 31463482 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency group (n = 25)
Number of subjects: 50
Study 31463482 — intervention group
Group type: COMPARATOR
Intervention: Nonpatency group (n = 25)
Number of subjects: 50
Study 29030478 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin therapy within 24 hours after admission
Number of subjects: 257
Study 29030478 — intervention group
Group type: COMPARATOR
Intervention: Delayed statin therapy on the seventh day after admission
Number of subjects: 257
Study 29030478 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin therapy
Number of subjects: 257
Study 29030478 — intervention group
Group type: COMPARATOR
Intervention: Delayed statin therapy
Number of subjects: 257
Study 25961617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride mouth rinse
Number of subjects: 30
Study 25961617 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinse
Number of subjects: 30
Study 24260889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) with 15 Gy, preoperative chemotherapy with paclitaxel/carboplatin, and radiosensitization with cisplatin
Number of subjects: 147
Study 24260889 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 147
Study 19291011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a + ribavirin 800 mg/day (Group A)
Number of subjects: 17
Study 19291011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a + ribavirin 400 mg/day (Group B)
Number of subjects: 17
Study 16458136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone for six months
Number of subjects: 26
Study 16458136 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 26
Study 15513697 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (309 +/- 88 mmol/day)
Number of subjects: 48
Study 10955697 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide (TAA)
Number of subjects: 0
Study 10955697 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (antihistamine)
Number of subjects: 0
Study 10955697 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 0
Study 8846524 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized heparin dosing protocol with a loading dose of 50 u/kg and continuous infusion of 15 u/kg/h, adjusted with a sliding scale to target WBAPPT in the range of 150-190 seconds.
Number of subjects: 31
Study 1519829 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 16
Study 1519829 — intervention group
Group type: COMPARATOR
Intervention: Control solutions
Number of subjects: 16
Study 6568354 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 - monthly measurements and reinforcement of behavioral, diet, and exercise components
Number of subjects: 15
Study 6568354 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 - monthly measurements
Number of subjects: 15
Study 6568354 — intervention group
Group type: COMPARATOR
Intervention: Group 3 - annual measurements
Number of subjects: 15
Study 31648401 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimplantation technique every 2 weeks for a maximum of four treatments
Number of subjects: 80
Study 31648401 — intervention group
Group type: COMPARATOR
Intervention: MMR intralesional injection at a dose of 0.5 ml every 2 weeks for a maximum of four treatments
Number of subjects: 80
Study 31648401 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimplantation technique
Number of subjects: 80
Study 31648401 — intervention group
Group type: COMPARATOR
Intervention: MMR intralesional injection
Number of subjects: 80
Study 28816894 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (ORIF)
Number of subjects: 301
Study 28816894 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 301
Study 24885514 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal HIV blog
Number of subjects: 261
Study 24885514 — intervention group
Group type: COMPARATOR
Intervention: Institutional HIV website
Number of subjects: 261
Study 23742058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute wood smoke exposure (mean particle concentration of 314±38 μg/m3)
Number of subjects: 14
Study 23742058 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14
Study 21284478 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine at 60% of TDI
Number of subjects: 223
Study 21284478 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine at 80% of TDI
Number of subjects: 223
Study 21284478 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine based on TDI and body weight
Number of subjects: 223
Study 19368584 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 208
Study 19368584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 16491577 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 kPa PIO2
Number of subjects: 13
Study 16491577 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kPa PIO2
Number of subjects: 13
Study 16491577 — intervention group
Group type: COMPARATOR
Intervention: 21 kPa PIO2 (control)
Number of subjects: 13
Study 15514265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinitol supplementation (2000 mg/day)
Number of subjects: 15
Study 15514265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-nutritive beverage)
Number of subjects: 15
Study 11075743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose Acetate (CA)
Number of subjects: 66
Study 11075743 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone (PS)
Number of subjects: 66
Study 11075743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose Acetate (CA) in ICU
Number of subjects: 66
Study 11075743 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone (PS) in ICU
Number of subjects: 66
Study 9228438 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin drugs
Number of subjects: 29000
Study 1428560 — intervention group
Group type: EXPERIMENTAL
Intervention: XPERT NCT (Reichert)
Number of subjects: 300
Study 1428560 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 300
Study 3880686 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene-hydrochlorothiazide
Number of subjects: 84
Study 3880686 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride-hydrochlorothiazide
Number of subjects: 84
Study 3305461 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime sodium (1 or 2 g intramuscular injections, three times daily)
Number of subjects: 100
Study 3305461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime arginine (1 or 2 g intramuscular injections, three times daily)
Number of subjects: 100
Study 3305461 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime sodium (1 g injections)
Number of subjects: 100
Study 3305461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime arginine (1 g injections)
Number of subjects: 100
Study 3305461 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime sodium (2 g injections)
Number of subjects: 100
Study 3305461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime arginine (2 g injections)
Number of subjects: 100
Study 31914105 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer specialist services (community-based, structured curriculum for recovery, up to 40 weekly sessions)
Number of subjects: 0
Study 31914105 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol adherent peer specialist services
Number of subjects: 0
Study 31914105 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (case management services)
Number of subjects: 0
Study 30574603 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite
Number of subjects: 35
Study 30574603 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant
Number of subjects: 35
Study 30574603 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 27756265 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counselling sessions and individual text message reminders for 16 weeks
Number of subjects: 20
Study 27756265 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual lifestyle)
Number of subjects: 20
Study 24720481 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive message against legalisation of doping
Number of subjects: 0
Study 24720481 — intervention group
Group type: COMPARATOR
Intervention: Persuasive message in favour of legalisation of doping
Number of subjects: 0
Study 24720481 — intervention group
Group type: EXPERIMENTAL
Intervention: High elaboration condition
Number of subjects: 0
Study 24720481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low elaboration condition
Number of subjects: 0
Study 23669489 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression decompression cardiopulmonary resuscitation plus an impedance threshold device (ACD+ITD)
Number of subjects: 2738
Study 23669489 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation (S-CPR)
Number of subjects: 2738
Study 19727956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine with or without adefovir dipivoxil
Number of subjects: 79
Study 19727956 — intervention group
Group type: COMPARATOR
Intervention: No antiviral treatment
Number of subjects: 79
Study 18699977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 0
Study 18699977 — intervention group
Group type: COMPARATOR
Intervention: Proton Pump Inhibitor (PPI) therapy
Number of subjects: 0
Study 16886198 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal aerosol delivery of alprazolam
Number of subjects: 0
Study 16886198 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal aerosol delivery of prochlorperazine
Number of subjects: 0
Study 16886198 — intervention group
Group type: COMPARATOR
Intervention: Rapid intravenous infusion
Number of subjects: 0
Study 14644862 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment (prednisone)
Number of subjects: 9
Study 14644862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study 10903217 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once a day)
Number of subjects: 8
Study 10903217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8877261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 16
Study 8877261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1891610 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled antiemetic therapy (PCAE)
Number of subjects: 20
Study 1891610 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered antiemetic therapy (NCAE)
Number of subjects: 20
Study 6150491 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam daily for 3 weeks
Number of subjects: 126
Study 6150491 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 3 weeks
Number of subjects: 126
Study 6150491 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam
Number of subjects: 126
Study 6150491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 30526375 — intervention group
Group type: EXPERIMENTAL
Intervention: Court Surface (CS)
Number of subjects: 40
Study 30526375 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass Surface (GS)
Number of subjects: 40
Study 30526375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tile Surface (TS)
Number of subjects: 40
Study 30747551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrothermally modified corn starch (HMS) ingestion (8% carbohydrate containing a total of 0.7 g·kg BM‐1·hr‐1; 2.8 kcal·kg BM‐1·hr‐1)
Number of subjects: 11
Study 30747551 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic dextrose
Number of subjects: 11
Study 29502050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic ballistic extracorporeal shock wave
Number of subjects: 77
Study 29502050 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided hormone injection
Number of subjects: 77
Study 27138575 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg orally per day) plus Bevacizumab (15 mg/kg intravenously once every 3 weeks)
Number of subjects: 350
Study 27138575 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (2.5 mg orally per day)
Number of subjects: 350
Study 24620850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga program (HYP)
Number of subjects: 31
Study 24620850 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC) music or art class
Number of subjects: 31
Study 21750975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Therapy (VT) - 5 sets of 1 min at 26 Hz, 6 mm peak-to-peak displacement
Number of subjects: 8
Study 21750975 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no VT)
Number of subjects: 8
Study 20555372 — intervention group
Group type: EXPERIMENTAL
Intervention: ARGININE (3.0 g of arginine, 300 mg of grape seed extract, and 300 mg of polyethylene glycol)
Number of subjects: 41
Study 20555372 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (microcrystalline cellulose)
Number of subjects: 41
Study 20555372 — intervention group
Group type: EXPERIMENTAL
Intervention: ARGININE
Number of subjects: 41
Study 20555372 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 41
Study 18278836 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) therapy
Number of subjects: 257
Study 18278836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) followed by Etanercept (ETN) therapy
Number of subjects: 257
Study 16029070 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 (disufenton sodium) continuous intravenous infusion for 72 hours, including a 1-hour loading infusion
Number of subjects: 179
Study 11763207 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 20
Study 11763207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral turbulence analysis (Group 1)
Number of subjects: 634
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration spectrum analysis (Group 1)
Number of subjects: 634
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral temporal mapping (Group 1)
Number of subjects: 634
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-domain analysis (Group 1)
Number of subjects: 634
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral turbulence analysis (Group 2)
Number of subjects: 634
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration spectrum analysis (Group 2)
Number of subjects: 634
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral temporal mapping (Group 2)
Number of subjects: 634
Study 9597413 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-domain analysis (Group 2)
Number of subjects: 634